Next-gen thiazole-sulphonamide hybrids as anti-lung cancer agents deciphered through in vitro, DFT, and docking synergy
In continuation of our previous work, novel sulphonamide–thiazole hybrids were synthesized and evaluated for anticancer activity against NCI–H226 lung carcinoma cells, with WI-38 fibroblasts as a normal control. Among the tested compounds, fluoro-substituted compound 14 exhibited the highest potency (IC50 = 16.10 μg/mL) and selectivity (SI = 183.79), while halogen- and nitro-substituted analogs (4–6) showed moderate activity. Quantum mechanical studies using DFT (B3LYP/6-311G(d,p), SMD solvent) rationalized the observed SAR, highlighting the role of electronic and steric effects in modulating activity. Molecular docking revealed stronger binding of compound 14 to EGFR (−8.2 kcal/mol) than TP53 (−7.1 kcal/mol), suggesting EGFR as its primary target, with TP53 interactions supporting apoptotic signalling. ADMET predictions indicated favourable drug-likeness, low toxicity, and non-mutagenicity. Molecular dynamics simulations over 100 ns confirmed that compound 14 forms highly stable complexes with both EGFR and TP53, preserving secondary structures, and consistent hydrogen-bonding and hydrophobic interactions, with MM-GBSA free energies of ~ –75 kcal mol−1. Free energy landscape and principal component analyses demonstrated conformational adaptability and long-term stability. Collectively, these results identify compound 14 as a potent, selective, and energetically favourable dual-target anticancer agent, providing a strong mechanistic foundation for further preclinical development.